Skip to main navigation Skip to search Skip to main content

Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma

  • Sarinya Kongpetch
  • , Apinya Jusakul
  • , Jing Quan Lim
  • , Cedric Chuan Young Ng
  • , Jason Yongsheng Chan
  • , Vikneswari Rajasegaran
  • , Tse Hui Lim
  • , Kiat Hon Lim
  • , Su Pin Choo
  • , Simona Dima
  • , Irinel Popescu
  • , Dan G. Duda
  • , Veerapol Kukongviriyapan
  • , Narong Khuntikeo
  • , Chawalit Pairojkul
  • , Steven G. Rozen
  • , Patrick Tan
  • , Bin Tean Teh*
  • *Corresponding author for this work
  • Khon Kaen University
  • Duke-NUS Medical School
  • National Cancer Centre
  • Singapore General Hospital
  • Fundeni Clinical Institute
  • Harvard University
  • Singapore Health Services
  • National University of Singapore
  • Agency for Science, Technology and Research, Singapore

Research output: Contribution to journal › Journal Article › peer-review

55 Scopus citations

Abstract

PURPOSE Cholangiocarcinoma (CCA) remains a disease with poor prognosis and limited therapeutic options. Identification of driver genetic alterations may lead to the discovery of more effective targeted therapies. CCAs harboring FGFR2 fusions have recently demonstrated promising responses to FGFR inhibitors, highlighting their potential relevance as predictive biomarkers. CCA incidence is high in the northeast of Thailand and its neighboring countries because of chronic infection with the liver fluke Opisthorchis viverrini (Ov). However, there are currently no available data on the prevalence of FGFR alterations in fluke-associated CCA in endemic countries. MATERIALS AND METHODS In this study, we performed anchored multiplex polymerase chain reaction target enrichment RNA sequencing of FGFR1-3, validated by fluorescence in situ hybridization and Sanger sequencing, in 121 Ov-associated and 95 non-Ov-associated CCA tumors. RESULTS Compared with non-fluke-associated CCA (11/95; 11.6%), FGFR2 fusions were significantly less common in fluke-associated CCA (1/121; 0.8%; P =.0006). All FGFR fusions were detected exclusively in intrahepatic CCAs and were mutually exclusive with KRAS/ERBB2/BRAF/FGFR mutations, pointing to their potential roles as oncogenic drivers. CONCLUSION FGFR2 fusions are rare in fluke-associated CCA, underscoring how distinct etiologies may affect molecular landscapes in tumors and highlighting the need to discover other actionable genomic alterations in endemic fluke-associated CCA.

Original languageEnglish
Pages (from-to)628-638
Number of pages11
JournalJCO global oncology
Volume6
DOIs
StatePublished - 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 by American Society of Clinical Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this